Literature DB >> 27216051

Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo.

Garrett C Moraski1, Yong Cheng2, Sanghyun Cho3, Jeffrey W Cramer4, Alexander Godfrey5, Thierry Masquelin5, Scott G Franzblau3, Marvin J Miller6, Jeffery Schorey7.   

Abstract

A panel of six imidazo[1,2-a]pyridine-3-carboxamides (IAPs) were shown to have low-micromolar activity against Mycobacterium avium strains. Compound ND-10885 (compound 2) showed significant activity in the lung, spleen, and liver in a mouse M. avium infection model. A combined regimen consisting of ND-10885 (compound 2) and rifampin was additive in its anti-M. avium activity in the lung. Our data indicate that IAPs represent a new class of antibiotics that are active against M. avium and could potentially serve as an effective addition to a combined treatment regimen.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27216051      PMCID： PMC4958206          DOI： 10.1128/AAC.00618-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

4.  Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients.

Authors:  Ryoji Maekura; Yoshinari Okuda; Atsusi Hirotani; Seigo Kitada; Touru Hiraga; Kenji Yoshimura; Ikuya Yano; Kazuo Kobayashi; Masami Ito
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

Authors:  Garrett C Moraski; Lowell D Markley; Philip A Hipskind; Helena Boshoff; Sanghyun Cho; Scott G Franzblau; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2011-06-09       Impact factor: 4.345

6.  Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis.

Authors:  Juan-Carlos Palomino; Anandi Martin; Mirtha Camacho; Humberto Guerra; Jean Swings; Françoise Portaels
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 7.  Review: Environmental mycobacteria as a cause of human infection.

Authors:  Samuel Halstrom; Patricia Price; Rachel Thomson
Journal:  Int J Mycobacteriol       Date:  2015-04-02

8.  Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.

Authors:  Garrett C Moraski; Patricia A Miller; Mai Ann Bailey; Juliane Ollinger; Tanya Parish; Helena I Boshoff; Sanghyun Cho; Jeffery R Anderson; Surafel Mulugeta; Scott G Franzblau; Marvin J Miller
Journal:  ACS Infect Dis       Date:  2014-12-27       Impact factor: 5.084

9.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.

Authors:  Katherine A Abrahams; Jonathan A G Cox; Vickey L Spivey; Nicholas J Loman; Mark J Pallen; Chrystala Constantinidou; Raquel Fernández; Carlos Alemparte; Modesto J Remuiñán; David Barros; Lluis Ballell; Gurdyal S Besra
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240
View more
  8 in total

1.  Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.

Authors:  Garrett C Moraski; Ryan Bristol; Natalie Seeger; Helena I Boshoff; Patricia Siu-Yee Tsang; Marvin J Miller
Journal:  ChemMedChem       Date:  2017-06-27       Impact factor: 3.466

2.  Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors.

Authors:  Bryan J Berube; Dara Russell; Lina Castro; Seoung-Ryoung Choi; Prabagaran Narayanasamy; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 3.  Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

Authors:  Sapna Bajeli; Navin Baid; Manjot Kaur; Ganesh P Pawar; Vinod D Chaudhari; Ashwani Kumar
Journal:  Front Cell Infect Microbiol       Date:  2020-11-23       Impact factor: 5.293

Review 4.  Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.

Authors:  Iram Khan Iqbal; Sapna Bajeli; Ajit Kumar Akela; Ashwani Kumar
Journal:  Pathogens       Date:  2018-02-23

5.  Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.

Authors:  Theresa O'Malley; Torey Alling; Julie V Early; Heather A Wescott; Anuradha Kumar; Garrett C Moraski; Marvin J Miller; Thierry Masquelin; Philip A Hipskind; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 6.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03

7.  Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.

Authors:  Garrett C Moraski; Nathalie Deboosère; Kate L Marshall; Heath A Weaver; Alexandre Vandeputte; Courtney Hastings; Lisa Woolhiser; Anne J Lenaerts; Priscille Brodin; Marvin J Miller
Journal:  PLoS One       Date:  2020-01-06       Impact factor: 3.240

8.  Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.

Authors:  Barbara Bosch; Michael A DeJesus; Nicholas C Poulton; Wenzhu Zhang; Curtis A Engelhart; Anisha Zaveri; Sophie Lavalette; Nadine Ruecker; Carolina Trujillo; Joshua B Wallach; Shuqi Li; Sabine Ehrt; Brian T Chait; Dirk Schnappinger; Jeremy M Rock
Journal:  Cell       Date:  2021-07-22       Impact factor: 41.582
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.